Prof. Orla Morrissey MB, BCh, FRACP, Grad Dip (Clin Epi), PhD, AFRACMA Infectious Diseases Physician,
Department of Infectious Diseases, Alfred Health
Department of Infectious Diseases, Monash University
Level 2, Burnet Building, 85 Commercial Road, Melbourne, Victoria, 3004, Australia T: +61 3 9076 2631 (Office) T: +61 9076 3009 (PA) F: +61 3 9076 2431
Orla,Thank you for this challenging question. The situation in St. Louis is similar - testing is prioritized to those with an epidemiologic link. If we had unlimited testing available I suspect we'd support testing anyone with the clinical syndrome.I'll ask Me-Linh and others to help me answer the following question that has troubled me. Although I think I understand the rationale for testing patients with an epidemiologic link (to maximize the value of the testing for containment purposes), if our approach to testing and containment would change if we were certain that community transmission is occurring, why are we reducing the likelihood of finding evidence of community transmission by deferring testing of patients without an epidemiologic link?Thanks.